Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler et autres
ch, au, ca, us, de, nl, es, gb, it (code pays fourni par la source)